This article is more than 5 years old. Information may no longer be current.
FDA approves store brand equivalent for Flonase
Click Here to Manage Email Alerts
The FDA recently approved a store brand equivalent of Flonase, fluticasone propionate 50 mcg spray, for over-the-counter treatment of hay fever and upper respiratory allergy symptoms in adults and children aged older than 4 years, according to a press release.
Perrigo and West-Ward Pharmaceuticals have entered an exclusive partnership agreement and have launched the equivalent of Flonase (GlaxoSmithKline) to be packaged and marketed as store brand or retailer “own label” brand.
“This product approval and launch demonstrates the power of Perrigo’s OTC platform,” John T. Hendrickson, MBA, CEO of Perrigo, said in a press release. “Our team has made significant efforts to bring this important product to our customers and consumers in the U.S. Important product launches like the store brand switch of fluticasone are what drive the Perrigo advantage by providing our consumers with high-quality, value alternatives in important treatment categories.”
In 2014, the FDA approved Flonase as an OTC treatment indicated for relief of all nasal and eye-related allergy symptoms, such as runny nose, sneezing, itchy nose, nasal congestion and itchy and watery eyes. As allergies, particularly nasal allergies, impact approximately 50 million people in the United States, the availability of store brand Flonase equivalent is expected to help alleviate this burden among patients.
“We are very pleased to be working with Perrigo to improve access to this important product for consumers interested in purchasing fluticasone propionate nasal spray over-the-counter,” Michael Raya, MS, president and CEO of West-Ward Pharmaceuticals, said in a release.